Skip to main content
Premium Trial:

Request an Annual Quote

Pathogenetix Raises $1.5M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pathogenetix, formerly called US Genomics, has raised about $1.5 million, it disclosed in a document filed with the US Securities Exchange Commission.

In an amended Form D, the Woburn, Mass.-based firm targets about $1.8 million in equity in the round. The target and amount raised to date are up from the $1.3 million target and amount raised that Pathogenetix had cited in an SEC filing last month. Pathogenetix also said in November that it sold $900,000 in debt instruments.

The company did not identify investors on the $1.8 million round but related persons listed include Augustine Lawlor, a managing partner at HealthCare Ventures; Steve Gullans, a managing director at Excel Venture Management; and Enrico Petrillo, also a managing director at Excel Venture Management. The three are also directors of Pathogenetix.

The company did not say how the funds will be used but said it is not in connection with a business combination, such as a merger, acquisition, or exchange offer.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.